Merck Reports observational Data for Risankizumab in Myasthenia gravis

Merck today announced observational results for risankizumab in patients with myasthenia gravis. The study demonstrated that risankizumab achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of myasthenia gravis and support the continued development of risankizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.